Rapid Cell-Based SARS-CoV-2 Neutralizing Antibody Assay Kit

Utilizing Our NEW Hybrid Alphavirus Particle Technology

Hot! New Omicron Variant Particles are Now Available!

The entry of SARS-CoV-2 into host cells is mediated by the trimeric transmembrane spike (S) glycoprotein. The S glycoprotein is surface-exposed and mediates entry into the host cells by binding to the human angiotensin-converting enzyme 2 receptor which makes the S glycoprotein a major target of neutralizing antibodies. Neutralizing antibodies blocking the S protein and receptor binding could prevent the virus from infecting host cells. Through the detection of the luminescence levels of target cells, it is possible to screen or verify the activity of these neutralizing antibodies.

Our product is fundamentally superior to any of our competitors due to the implementation of our newly developed Ha-CoV-2 particle. Ha-CoV-2 is a newly developed hybrid SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid expression of reporter genes (luciferase or GFP) in target cells (Hetrick et al., 2020). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirus-based vector for rapid (4 hours) and robust expression of reporter genes. Ha-CoV-2 represents a major technology advancement in the development of SARS-CoV-2 pseudoviruses, and serves as platforms for rapid and robust quantification of neutralizing antibodies, viral mutants, and antiviral drugs (Dabbagh et al., 2021; He et al., 2021).

Virongy offers pre-assembled Ha-CoV-2 reporter pseudovirions and derived S protein variants. We also help customers to perform antiviral drug screening and quantification of neutralizing antibodies. For more information, please contact us by email: info@virongy.com

 

Ha-CoV-2 Major advances

  • Faster speed – As fast as 4 hours for the detection of reporter expression for Ha-CoV-2 versus 2-3 days for S protein pseudotyped lentivirus. (Maximum expression between 12-18 hours)
  • More robust reporter signal - Ha-CoV-2 takes advantage of the rapid and robust gene expression capacity of an alphavirus vector for reporter expression.
  • High fidelity in particle structure – Ha-CoV-2 contains all 4 SARS-CoV-2 structural proteins (S, M, E, and N), but no structural proteins from other viruses. In contrast, lenti- and VSV- pseudoviruses contain only the S protein from SARAS-CoV-2, and multiple structural proteins from other viruses, such as HIV-1 Gag and Pol.
  • Strong correlation (coefficient value r2 = 0.87) with wild-type SARS-CoV-2 in neutralizing antibody assays (Hetrick et al., 2020).

 

Rapid Cell-Based SARS-CoV-2 Neutralizing Antibody Assay Kits:

Customize your kit by selecting from our list of SARS-CoV-2 spike mutants or variants:

SARS-CoV-2 Spikes Available Mutations Sequence Derived Accession Numbers
D614G Single Mutant Spike D614G MN908947.3
Alpha (B.1.1.7)

UK

Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y145del EPI_ISL_581117
(B.1.1.207)

US-MD

Spike D614G, Spike E484K, Spike P681H EPI_ISL_778908
(B.1.1.298)

Demark

Spike D614G, Spike H69del, Spike I692V, Spike M1229I, Spike V70del, Spike Y453F EPI_ISL_616802
(B.1.2)

US-CA

Spike D614G, Spike E484K, Spike G446V, Spike Y453F EPI_ISL_833413
(B.1.258)

US-FL

Spike D614G, Spike H69del, Spike N439K, Spike V70del EPI_ISL_755592
Beta (B.1.351) South Africa Spike A243del, Spike A701V, Spike D80A, Spike D215G, Spike D614G, Spike E484K, Spike K417N, Spike L242del, Spike L244del, Spike N501Y EPI_ISL_678597
Epsilon (B.1.429)

US-CA-LA

Spike A222V, Spike D614G, Spike L452R, Spike S13I, Spike W152C EPI_ISL_847764
(B.1.494)

US-NY

Spike A262S, Spike D614G, Spike D796Y, Spike H49Y, Spike L452R, Spike N501Y, Spike P681R, Spike Q613H EPI_ISL_826591
Gamma (P.1) Brazil Spike D138Y, Spike D614G, Spike E484K, Spike H655Y, Spike K417T, Spike L18F, Spike N501Y, Spike P26S, Spike R190S, Spike T20N, Spike T1027I, Spike V1176F EPI_ISL_833136
Kappa (B.1.617.1) India Spike E154K, Spike L452R, Spike E484Q, Spike D614G, Spike P681R, Spike Q1071H EPI_ISL_1663368

 

Eta (B.1.525)

Japan

Spike A67V, Spike D614G, Spike E484K, Spike F888L, Spike H69del, Spike Q52R, Spike Q677H, Spike V70del, Spike Y144del EPI_ISL_1198845
Epsilon (B.1.427/429)

US-TX

Spike D614G, Spike E484K, Spike L452R, Spike S13I, Spike W152C EPI_ISL_1444002
Delta (B.1.617.2)

India

Spike T19R, Spike del157/158, Spike L452R, Spike T478K, Spike D614G, Spike P681R, Spike D950N EPI_ISL_1841283
Delta Plus (AY.2)

USA

Spike T19R, Spike V70F, Spiked del157/158, Spike A222V, Spike K417N, Spike L452R, Spike T478K, Spike D614G, Spike P681R, Spike D950N EPI_ISL_2929979
Lambda (C.37) Peru

 

Spike G75V, Spike T76I, Spike R246N, Spike del247/253, Spike L452Q, Spike F490S, Spike D614G, Spike T859N EPI_ISL_2921276
Mu (B.1.621) Spike T95I, Spike Y144S, Spike Y145N, Spike R346K, Spike E484K, Spike N501Y, Spike D614G, Spike P681H, Spike D950N

 

EPI_ISL_2178402
Delta Plus (AY4.2) Spike T19R, Spike T95I, Spike G142D, Spike Y145H, Spike E156G, Spike del157/158, Spike A222V, Spike L452R, Spike T478K, Spike D614G, Spike P681R, Spike D950N  

EPI_ISL_6777023

Omicron (B.1.1.529) Spike A67V, Spike H69del,Spike V70del, Spike T95I, Spike G142D, Spike V143del, Spike Y144del, Spike Y145del, Spike N211del, Spike L212I, Spike ins214EPE, Spike G339D, Spike S371L, Spike S373P, Spike S375F, Spike K417N,  Spike N440K, Spike G446S, Spike S477N, Spike T478K, Spike E484A, Spike Q493R,  Spike G496S, Spike Q498R, Spike N501Y, Spike Y505H, Spike T547K,  Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike N856K, Spike Q954H, Spike N969K, Spike L981F

 

EPI_ISL_6640919

 

Rapid Cell-Based Neutralization Assay Kit Components:

  • HA-CoV-2(Luc) Particles 5.5 mL
  • Standard SARS-CoV-2 Neutralizing Antibody 50 μL
  • 5X Cell Lysis Buffer 2 mL
  • Luciferase Buffer Solution 5.5 mL
  • D-Luciferin Solution 110 μL
  • HEK293T(ACE2/TMPRSS2) 1mL (5x106cells) [RCNAK-01 Only]

View the protocol